Central Monitoring Platform (CMP)

Solutions / RBQM / CMP

Continuous Risk Detection Across Every Study, Every Site, Every Data Source

CluePoints Central Monitoring Platform (CMP) continuously interrogates clinical, operational, safety, and lab data across every site and study in your portfolio, applying advanced statistical methods that go far beyond threshold-based Key Risk Indicator (KRI) checks. The result: quality risks that traditional monitoring misses are surfaced earlier, documented automatically, and ready for proportionate action under ICH E6(R3).

Request a Demo

Explore RBQM

Risk Intelligence Across Your Entire Clinical Portfolio

CluePoints CMP ingests clinical, operational, safety, and lab data from every active study and every site, from any Electronic Data Capture (EDC) or Clinical Trial Management System (CTMS) vendor, and applies multivariate statistical methods simultaneously. The capabilities below work together to give Sponsors and Contract Research Organizations (CROs) a complete, continuously updated picture of quality risk across the entire portfolio.

Key Risk Indicators (KRIs)

Track protocol-defined metrics against pre-set thresholds for every site, automatically ranking sites against peer benchmarks so monitoring effort concentrates where data signals genuine risk rather than where it was always scheduled.

Quality Tolerance Limits (QTLs)

Monitor trial-level critical metrics against pre-defined tolerances, automatically document every breach, investigation, and resolution, and generate the inspection-ready evidence trail ICH E6(R3) requires for every quality deviation.

Central Statistical Monitoring

Apply multivariate statistical methods continuously across all collected clinical and operational data to surface co-occurring anomalies, systemic patterns, and data integrity risks that single-metric KRI thresholds are structurally unable to detect.

Duplicate & Suspicious Patient Detection

Automatically identify patient pairs that may represent duplicate records or statistically improbable data profiles, surfacing potential fabrication and data entry errors before they reach database lock or regulatory review.

Data Quality Analytics (DQA)

Apply statistical analysis to audit trail data across large study datasets to identify patterns of data manipulation, anomalous entry behavior, and digit preference that manual review cannot detect at scale.

Business Intelligence (BI / BEYOND)

Explore safety, operational, and enrollment data through fully configurable BEYOND dashboards, giving clinical operations, Data Management (DM), and leadership teams the views they need, in the format they need, without data science support.

How Teams Use CluePoints CMP

See Risk Signals Across Your Entire Portfolio,  Not Study by Study

Most monitoring programs are configured to catch what their pre-set thresholds were designed to find. CluePoints CMP catches what they miss. By continuously applying multivariate statistical methods across all clinical, operational, safety, and lab data from every active study simultaneously, CMP surfaces co-occurring anomalies and systemic patterns across the portfolio. These are the signals that correlate with inspection findings but are often missed by single-domain KRI checks or manual study-level listing reviews. Every signal flows directly into a governed, traceable workflow.

Consistent Quality Governance Across Every Active Study

CMP tracks KRIs and Quality Tolerance Limits (QTLs) centrally across all studies in a portfolio, giving operations leaders a unified view of threshold breaches, emerging risk trends, and site performance outliers, with updates as data arrives. When a site's KRI crosses a threshold, CMP automatically documents the metric, threshold, deviation, and timestamp. Inspection narratives emerge from routine oversight, not from retrospective reconstruction the week before an audit.

Inspection Evidence Generated Automatically as You Work

Regulators don’t just want to know what risks were detected. They want to see how they were detected, what the response was, and whether decisions were proportionate and traceable. CMP captures that complete evidence thread automatically: risk assessment and Critical-to-Quality (CtQ) factor mapping, KRI and QTL configuration rationale, signal detection, investigation, action taken, and resolution confirmed, all in a 21 CFR Part 11-compliant environment. CluePoints technology is used by regulators themselves to interrogate clinical data. Sponsors running CMP can see what inspectors will see before they arrive.

REGULATORY-GRADE RBQM

Built for What Regulators Actually Inspect

ICH E6(R3) establishes central data review as a core requirement of Risk-Based Quality Management (RBQM). Regulatory-grade RBQM means that review is continuous, methods are transparent and validated, and every decision is documented in a traceable evidence trail. CMP operationalizes all three requirements. The same statistical methods CMP applies are used by regulators when they interrogate clinical data and select sites for inspection, giving Sponsors advance visibility into where inspection focus is likely to fall.

Download the White Paper

PART OF THE RBQM PLATFORM

Detection Is the Starting Point. RBQM Is the Outcome.

CluePoints CMP provides the portfolio-wide risk intelligence layer. CluePoints Site Profile & Oversight Tool (SPOT) converts those signals into prioritized site-level action. Together, CMP and SPOT form CluePoints RBQM: end-to-end oversight from signal detection through monitoring decisions to outcome documentation. CMP alone surfaces the risk. RBQM closes the loop.

Explore CluePoints RBQM